Replies to post #6275 on GTC Biotherapeutics (fka GTCB)

[exwannabe]

Insider purchases wrt SEC.

News on trial results would not be a problem, because he would not have known the data at the time he bought. Nobody knows trial results before unblinding.

As to a partner, as long as the status was reasonably consistent with the public statements, that is fine.

Problems would be if he had already inked a great deal (or already had top line results in hand).

The amount of the buy doesn't matter. But in practice, the SEC would obviously not care about a minor purchase. The only recent case I remember of the SEC taking action on a buy was when Murdoch bought DowJones, and some guy from Asia bought a ton of calls before the news was out.

[DewDiligence]

The timing of a transaction——rather than the size—is what determines whether the transaction violates insider-trading rules.